Genetic Technologies Limited
GNTLF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.44 | 0.02 | 0.03 | -0.06 |
| FCF Yield | -0.03% | -36.22% | -31.45% | -11.43% |
| EV / EBITDA | -233.93 | -2.92 | -4.43 | -2.43 |
| Quality | ||||
| ROIC | 48.26% | -122.03% | -96.63% | -39.02% |
| Gross Margin | 100.00% | 58.25% | -50.05% | -26.99% |
| Cash Conversion Ratio | 0.02 | 1.01 | 0.61 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 643.52% | 690.55% | 439.09% | 336.90% |
| Free Cash Flow Growth | 98.62% | -45.33% | -56.95% | 8.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.03 | 1.64 | 1.23 |
| Interest Coverage | -33.01 | -89.50 | -401.72 | -335.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 9.71 | 14.97 | 17.66 |
| Cash Conversion Cycle | 31.58 | -16.34 | 2.33 | -4.20 |